EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Biological Evaluation of Benzimidazol‐2‐One Hybrids as Potential Anti‐Alzheimer's Disease Agents

Fatih Yılmaz iD, Emre Menteşe iD, Ozan Emre Eyüpoğlu iD, Bahittin Kahveci, Mustafa Emirik iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Fatih Yılmaz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Process Technology, Vocational School of Technical Sciences, Recep Tayyip Erdogan University, Rize, Turkey. Hauptthemen laut MEDLINE: Alzheimer Disease, Cholinesterase Inhibitors, Benzimidazoles, Monoamine Oxidase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recep Tayyip Erdogan Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder for which single‐target therapies often provide insufficient benefit, motivating the development of multi‐target‐directed ligands (MTDLs). In this study, a novel series of benzimidazolone‐based hybrids incorporating piperazine, coumarin, and triazole moieties was designed, synthesized, and evaluated for inhibitory activity against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase‐B (MAO‐B), as well as antioxidant potential via on‐line HPLC‐based assays. Structures were confirmed by 1 H‐NMR, 13 C‐NMR (APT), and elemental analysis. Several compounds showed notable, micromolar‐range inhibitory activity, though less potent than the reference drugs. Kinetic analysis showed that the leading compounds inhibited their respective enzymes via a mixed‐type mechanism. Compound 1 showed the strongest AChE inhibition (IC 50 = 0.777 ± 0.014 µM), compound 9b the highest BChE inhibition (IC 50 = 0.659 ± 0.005 µM), and compound 9c the most potent MAO‐B inhibition (IC 50 = 2.431 ± 0.003 µM). Compound 8a showed the highest CUPRAC copper‐reducing capacity, while 7c displayed the strongest DPPH radical‐scavenging activity. Liposomal formulations of 4c , 7c , and 8a exhibited enhanced antioxidant responses relative to their free forms. In silico ADME predictions (SwissADME) indicated favorable drug‐likeness and blood–brain barrier permeation for the compact scaffold (compound 1 ) and the piperazine‐based hybrids, whereas the larger bis‐conjugated derivatives were limited by high polarity and molecular weight. Overall, these benzimidazolone‐based hybrids represent promising multi‐target candidates for AD drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCholinesterase InhibitorsBenzimidazolesMonoamine Oxidase InhibitorsDrug DesignButyrylcholinesteraseHumansAntioxidantsAcetylcholinesteraseMonoamine OxidaseStructure-Activity RelationshipAnimalsMolecular Docking SimulationCoumarins

Stichwörter der Autor:innen

AChEAlzheimer's diseaseBChEMAO‐Bbenzimidazolonecoumarinonline HPLC analysistriazole

Substanzen

Cholinesterase InhibitorsBenzimidazolesMonoamine Oxidase InhibitorsButyrylcholinesteraseAntioxidantsAcetylcholinesteraseMonoamine OxidasebenzimidazoloneCoumarinscoumarin

Autor:innen und Institutionen

  • Department of Chemistry and Chemical Process Technology, Vocational School of Technical Sciences, Recep Tayyip Erdogan University, Rize, Turkey.
  • Department of Chemistry, Faculty of Art and Sciences, Recep Tayyip Erdogan University, Rize, Turkey.
  • Department of Biochemistry, School of Pharmacy, Istanbul Medipol University, Istanbul, Turkey.
  • Department of Nutrition and Dietetics, Faculty of Health Sciences, Karadeniz Technical University, Trabzon, Turkey.

ORCID-Profile: Fatih Yılmaz, Emre Menteşe, Ozan Emre Eyüpoğlu, Mustafa Emirik

Förderung

  • Recep Tayyip Erdogan Üniversitesi

Zitieren

APA

Yılmaz, F., Menteşe, E., Eyüpoğlu, O. E., Kahveci, B., & Emirik, M. (2026). Design, Synthesis, and Biological Evaluation of Benzimidazol‐2‐One Hybrids as Potential Anti‐Alzheimer's Disease Agents. Drug Development Research. https://doi.org/10.1002/ddr.70369

Vancouver

Yılmaz F, Menteşe E, Eyüpoğlu OE, Kahveci B, Emirik M. Design, Synthesis, and Biological Evaluation of Benzimidazol‐2‐One Hybrids as Potential Anti‐Alzheimer's Disease Agents. Drug Development Research. 2026. doi:10.1002/ddr.70369

BibTeX
@article{Ylmaz2026,
  author = {Yılmaz, Fatih and Menteşe, Emre and Eyüpoğlu, Ozan Emre and Kahveci, Bahittin and Emirik, Mustafa},
  title = {Design, Synthesis, and Biological Evaluation of Benzimidazol‐2‐One Hybrids as Potential Anti‐Alzheimer's Disease Agents},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70369}
}
Kostenlos starten →